As the nation grapples with unemployment & state budgets shrink amid #COVID-19, Nevada has a model that policy officials could implement and test to reemploy dislocated workers: It’s helping millions find jobs faster AND saving state money. arnoldventures.org/stories/nevada…#VPDebates
The future of criminal justice reform is on the ballot now. California voters could pass the single largest criminal justice reform ever put up for a popular election by voting #YESonProp25 arnoldventures.org/stories/suppor…#VPDebate
Race-based policing is a serious problem police departments must confront. An NYU Public Safety Lab analysis of NYPD misconduct complaints found a racial pattern: Precincts with higher % of Black residents had higher-than-expected number of misconduct complaints. #VPDebate
The data shows race is a key determinant in whether people feel their local police officers are treating them properly and with respect, and it found a small number of officers were responsible for a high number of complaints. #Debates2020
The data can be used to focus on the officers who have the largest numbers of misconduct complaints, and this research should be a lesson for leaders in law enforcement about how misconduct complaints can be reduced. arnoldventures.org/stories/nyu-an…#VPDebate
The American people care about drug prices and the unaffordability of health care for families, employers and taxpayers across the U.S. We should be talking about this. #VPDebate
They care about affordable and accountable #highered. We should be talking about this. #VPDebate
They care about the other public health crisis in this country: the #opioidepidemic, which has only been exacerbated with more lives lost amid #COVID19. We should be talking about this. #VPDebate
• • •
Missing some Tweet in this thread? You can try to
force a refresh
“I’m so grateful for #Gleevec. It keeps me alive. But the price tag ($10k/month) constantly hangs over my head.”
"When I'm on Enbrel, I don't have symptoms... But I also have to carry the fear knowing all this could be ripped away." Enbrel is priced at $6k per month.
First up: autoimmune drug Enbrel. Even though the primary patent on Enbrel expired in 2010, $AMGN has filed more than 50 additional patents on the drug to thwart cheaper competition, according to analysis by @IMAKglobal (1/) statnews.com/2020/09/29/dru…
Medicare spent hundreds of millions of $$$ more on Copaxone each year because of its inability to negotiate directly @46brooklyn@akesselheim
Even Teva’s own employees could not afford Copaxone at its price. One said she could no longer afford Copaxone because she would have to pay $1,673.33 out of pocket as compared to $12 for Mylan’s generic product.
After Mylan introduced a lower-priced generic version of Copaxone 40 mg/ml in October 2017, Teva implemented several new exclusionary tactics to limit generic competition and maintain profits.
First up: #Revlimid, a drug that costs $20k for a 28-day supply. The Committee reviewed more than 50k pages of internal communications & data from 2009 to now. Since Revlimid launched in '05, Celgene raised the price 22 times (1/) oversight.house.gov/sites/democrat…
After Bristol Myers Squibb obtained the rights to Revlimid last November, it raised the price again to $763/pill. The price has tripled in 15 years (2/)
Revlimid is a textbook case of profits over patients (3/)
Pres. Trump’s executive order on surprise billing just punts the issue back to the Congress. The White House & Congress need to stop dithering and agree to a comprehensive legislative solution. (1/)
Pres. Trump *should* throw his weight behind the existing bipartisan agreement to end surprise billing that Congress has *failed* to pass (2/)
As a reminder: surprise medical billing is a predatory practice that occurs when patients receive unexpected and often expensive bills from hospitals and physicians that are not in their insurance network. (3/) arnoldventures.org/stories/surpri…
[THREAD] The new @dataforjustice report examining enforcement in New York City from 2003 to 2018 is out!
Read the top findings below ⬇️
Overall, enforcement increased sharply between 2003 and 2011 and then dropped from 2011 to 2018. Despite the declines observed, arrest rates are notably still higher than the lows recorded in the 1980s. /1
The data also show that racial disparities continued to be an issue through these ups and downs. In fact, in 2018, for every enforcement action taken by the NYPD against a white person almost six enforcement actions were taken against Black people. /2